ebs

Documents about ebs

• Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex#895645ClinicalTrials.gov
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-10 — Material Contract (0001367644-19-000016)#613871SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-11 — Material Contract (0001367644-19-000016)#613872SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-12 — Employment Agreement (0001367644-19-000016)#613873SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-13 — Employment Agreement (0001367644-19-000016)#613874SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-14 — Employment Agreement (0001367644-19-000016)#613875SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-15 — Settlement Agreement (0001367644-19-000016)#613876SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-16 — Employment Agreement (0001367644-19-000016)#613877SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-17 — Employment Agreement (0001367644-19-000016)#613878SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-18 — Employment Agreement (0001367644-19-000016)#613879SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-19 — Settlement Agreement (0001367644-19-000016)#613880SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-20 — Employment Agreement (0001367644-19-000016)#613881SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-21 — Employment Agreement (0001367644-19-000016)#613882SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-45 — Material Contract (0001367644-19-000016)#613883SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-46 — Material Contract (0001367644-19-000016)#613884SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-47 — Material Contract (0001367644-19-000016)#613885SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-51 — License Agreement (0001367644-19-000016)#613886SEC EDGAR Material Contracts
• Emergent BioSolutions Inc. (EBS) — Exhibit 10-52 — License Agreement (0001367644-19-000016)#613887SEC EDGAR Material Contracts
• The Landscape of Women's Health Podcasts: A Scoping Review.#636630NCBI PubMed Central
• An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)#1095660ClinicalTrials.gov
• O'Toole v EBS Designated Activity Company and Anor (Approved) [2026] IEHC 247 (28 April 2026)#184345BAILII Ireland
• Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study#1164680ClinicalTrials.gov
• EBS and in-beam $γ$-ray investigation of FCVA-prepared Cr$_2$O$_3$ targets for low-energy $^{16}$O+$^{16}$O fusion experiments#973752arXiv (All)
• Computational Drug Repurposing for All EBS Cases#1010002ClinicalTrials.gov
• Patch Test Results With the European Baseline Series, 2021/2022-Joint European Results of the ESSCA(A) and the EBS(B) Working Groups of the ESCD, and the GEIDAC(C).#265406NCBI PubMed Central
• Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex#906336ClinicalTrials.gov
• Oracle EBS Managed Service Provision — Greater Manchester Police — Version 1 Solutions Limited#608230UK Contracts Finder